Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile.
Immune-mediated necrotizing myopathy (IMNM) is considered one of the idiopathic inflammatory myopathies, comprising dermatomyositis, polymyositis, and inclusion body myositis. The heterogeneous group of necrotizing myopathies shows a varying amount of necrotic muscle fibers, myophagocytosis, and a sparse inflammatory infiltrate. The underlying immune response in necrotizing myopathy has not yet been addressed in detail. Affected muscle tissue, obtained from 16 patients with IMNM, was analyzed compared with eight non-IMNM (nIMNM) tissues. Inflammatory cells were characterized by IHC, and immune mediators were assessed by quantitative real-time PCR. We demonstrate that immune- and non-immune-mediated disease can be distinguished by a specific immune profile with significantly more prominent major histocompatibility complex class I expression and complement deposition and a conspicuous inflammatory infiltrate. In addition, patients with IMNM exhibit a strong type 1 helper T cell (T1)/classically activated macrophage M1 response, with detection of elevated interferon-γ, tumor necrosis factor-α, IL-12, and STAT1 levels in the muscle tissue, which may serve as biomarkers and aid in diagnostic decisions. Furthermore, B cells and high expression of the chemoattractant CXCL13 were identified in a subgroup of patients with defined autoantibodies. Taken together, we propose a diagnostic armamentarium that allows for clear differentiation between IMNM and nIMNM. In addition, we have characterized a Th1-driven, M1-mediated immune response in most of the autoimmune necrotizing myopathies, which may guide therapeutic options in the future.
Department of Neuropathology, Charité-Universitätsmedizin, Charité Campus Mitte, Charitéplatz 1, Berlin, Germany.
Corinna
C
Preuße
Hans H
HH
Goebel
Josephin
J
Held
Oliver
O
Wengert
Franziska
F
Scheibe
Kerstin
K
Irlbacher
Arend
A
Koch
Frank L
FL
Heppner
Werner
W
Stenzel
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001402:B-Lymphocytes / Q000276:immunology; D001706:Biopsy; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002196:Capillaries / Q000276:immunology / Q000473:pathology; D002452:Cell Count; D002675:Child, Preschool; D003165:Complement System Proteins / Q000276:immunology; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D007109:Immunity / Q000276:immunology*; D008264:Macrophages / Q000276:immunology* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000098:blood supply / Q000276:immunology / Q000473:pathology / Q000648:ultrastructure; D009220:Myositis / Q000276:immunology* / Q000473:pathology*; D060888:Real-Time Polymerase Chain Reaction; D012508:Sarcolemma / Q000276:immunology / Q000473:pathology; D018417:Th1 Cells / Q000276:immunology* / Q000473:pathology*; D055815:Young Adult
D015395:Histocompatibility Antigens Class I; D003165:Complement System Proteins